Tonix Pharmaceuticals Clinical Trials Underway Investigating New Drugs For Fibromyalgia, PTSD, and Tension Headache

Tonix Pharmaceuticals Clinical Trials Underway Investigating New Drugs For Fibromyalgia, PTSD, and Tension Headache
Clinical-stage pharmaceutical company Tonix Pharmaceuticals Holding Corp. in conjunction with announcing its second quarter 2015 financial results, reports progress in developing next-generation medicines for treating fibromyalgia, post-traumatic stress disorder (PTSD), and episodic tension-type headache. "In the first half of this year, we achieved our goal of initiating efficacy studies in tension headache, post-traumatic stress disorder, and fibromyalgia, all large therapeutic indications," comments Tonix's chairman and CEO Seth Lederman, M.D. "We look forward to reporting results from each of these three trials in 2016 as we advance our programs through the clinical development process." Tonix ended the June 30, 2015 quarter with $48.m7 million in cash and cash equivalents, and raised $18.7M in net proceeds from an underwritten offering completed in July 2015. Recent Clinical Highlights and Upcoming Milestones Reported Tonix commenced a 500-patient Phase 3 AFFIRM clinical study of Tonmya (cyclobenzaprine HCl sublingual tablets, 2.8 mg), its an investigational medication candidate for treating fibromyalgia, that may help improve fibromyalgia symptoms and sleep quality, in May, 2015. The clinical study, called AFFIRM, is a randomized, double-blind, placebo-controlled, 12-week trial of Tonmya taken sublingually at bedtime daily. The primary efficacy endpoint is a 30 percent pain responder analysis at week 12, and Tonix expects to report top-line results during the second half of 2016, noting that fibromyalgia afflicts an estimated five to 15 million Americans, with physicians and patients repo
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *